Description
Taking the latest research and sharing insights from clinicians about implementing it in clinical practice, Science to Medicine features real-world examples from a variety of practice settings and clinician types—operationalizing research to improve patient care.
CME/CE Information
Clinicians in Action Operationalizing Science to Medicine to Improve Patient Care
- Jointly provided by Postgraduate Institute for Medicine and National Institute on Drug Abuse
- Release date: July 15, 2021
- Expiration date: October 11, 2024
- Estimated time to complete each module:
- Medication Treatment for Opioid Use Disorder: 45 minutes
- Screening for Substance Use: 45 minutes
- Naloxone in the Pharmacy Setting: 30 minutes
- Managing Patients’ Pain: Insights from a Primary Care Provider: 30 minutes
- Total estimated time to complete activity: 2.5 hours
- Mechanism for the learner to contact PIM
Target Audience
This activity is intended for physicians, physician assistants, pharmacists, registered nurses, nurse practitioners/other APRN and dentists engaged in the care of patients with substance use disorder/addiction in emergency medicine, federally qualified health center, inpatient hospital, pediatric/adolescent medicine, primary care, pain management, dental, family medicine/obstetrics, or pharmacy settings.
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe recent peer-reviewed research about medication treatment for opioid use disorder; screening for substance use; providing naloxone in the pharmacy setting; managing patients’ pain.
- Demonstrate when and how screening for substance use should occur.
- Identify appropriate substance use screening and assessment tools.
- Explain next steps to take after receiving a positive screen from a patient.
- Explain strategies to patients, families, and colleagues about how to begin medication treatment for opioid use disorder.
- Practice how to provide medication treatment for opioid use disorder in your practice.
- Describe medications to treat patients with opioid use disorder.
- Explain the importance of naloxone distribution by pharmacists.
- Develop steps to identify people at risk of overdose and explain how naloxone distribution can be implemented in the pharmacy setting.
- Evaluate pain treatment options that will be appropriate for patients.
- Faculty and Disclosure of Conflicts of Interest
Faculty Name/Professional Credential Title and Affiliation Krista Brucker, MD Alister Martin, MD, MPP Emergency Physician Massachusetts General Hospital (MGH) Founder - Get Waivered Amanda Davis-Houchen, FNP-C, CEN LifeSpring Community Health Services, Indiana Clarissa Johnston, MD Associate Professor of Medicine
Department of Internal Medicine,
Divisions of Hospital Medicine and Palliative Care
Dell Medical School at the University of Texas, AustinRichard Bottner, PA-C Assistant Professor, Department of Internal Medicine, Dell Medical School at The University of Texas at Austin Elizabeth Bennett, RN, BSN Deepa Camenga, MD Pediatrician and Addiction Medicine Specialist Associate Professor, Yale School of Medicine, New Haven, Connecticut Marla D. Kushner, DO, SC President Marla D. Kushner, DO, S.C. Bernard Stuetz, PA-C, MA Physician Assistant
Primary Care Practice, Philadelphia, PennsylvaniaSteven Stanos, DO Executive Medical Director, Rehabilitation and Performance Medicine
Medical Director, Swedish Health System, Pain Medicine and Services
Seattle, WashingtonBrett H. Kessler, DDS Trustee, American Dental Association Stephanie Botts, BSDH TOWN Center Dentistry and Orthodontics Tipu V. Khan, MD, FAAFP California Hospital Medical Center/University of Southern California Obstetrics Fellowship
Board Certified in Family and Addiction Medicine
Medical Director of Prototypes Southern California
Fellowship Director of The Ventura County Medical Center Addiction Medicine Fellowship
Core Faculty at The Ventura Family Medicine Residency
Assistant Clinical Professor at University of California at Los Angeles, David Geffin School of MedicineJennifer George Coffaro, PA-C University of Kentucky HealthCare, Kentucky Children’s Hospital,
Department of Pediatrics
Division of Adolescent Medicine and Young Parents Program LexingtonDawn Lee Garzon Maaks PhD, CPNP-PC, PMHS, FAANP Nurse Practitioner LifeStance Health St. Peters and Chesterfield, Missouri Anita N. Jacobson, PharmD Clinical Professor University of Rhode Island (URI) College of Pharmacy William Becker, M.D. Associate Professor, Yale School of Medicine
Core Investigator, Pain Research, Informatics, Multimorbidities & Education Center of Innovation
VA Connecticut Healthcare SystemDisclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Steven Stanos, DO: Consulting fees from Hisamitsu, Lilly, Emergent BioSolutions, Pfizer, BDSI, Vertex.
Tipu V. Khan, MD, FAAFP: Consulting fees from Abbvie
Dawn Lee Garzon Maaks PhD, CPNP-PC, PMHS, FAANP: Royalties from Elsevier, Burns' Pediatric Primary Care
Anita N. Jacobson, PharmD: Consulting fees from American Pharmacists Association
The following faculty have nothing to disclose: Krista Brucker, MD; Alister Martin, MD, MPP; Amanda Davis-Houchen, FNP-C, CEN; Clarissa Johnston, MD; Richard Bottner, PA-C; Elizabeth Bennett, RN, BSN; Deepa Camenga, MD; Marla D. Kushner, DO, SC; Bernard Stuetz, PA-C, MA; Brett H. Kessler, DDS; Stephanie Botts, BSDH; Jennifer George Coffaro, PA-C; and William C. Becker, MD
The PIM planners and others have nothing to disclose.
The following planners and others have nothing to disclose: Michelle Corbin from the National Institute on Drug Abuse, Erika Capinguian, Susan Hayashi, Ashley Matus and Laura Nolan from JBS International, Inc.
- Method of Participation and Request for Credit
In order to obtain your CE certificate, please follow the steps below at the conclusion of the activity:
- Go to cmeuniversity.com
- Login or Create a New Account (will take less than 1 minute)
- If you receive a message when creating a new account that “the email you entered is already in use”, please click the Forgot my Username or Password link to have your Username and Password sent to you via email
- After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page
- Type in 16518 at the top of the page, “Find Post-Test/Evaluation by Course”, and click enter
- Click on the activity title when it appears
- Choose the type of credit you desire
- Complete the Post-test with a passing score of 75% or better
- Complete the online Evaluation
- Receive an immediate CE Certificate to download and/or print for your files
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better (if applicable) and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.
- Credit Designation
Joint Accreditation Statement
Image
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the National Institute on Drug Abuse. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Each course is approved for the following number of AMA PRA Category 1 Credit(s)™:
Medication Treatment for Opioid Use Disorder: 0.75 Screening for Substance Use Credit: 0.75 Naloxone in the Pharmacy Setting: 0.5 Managing Patients’ Pain: Insights from a Primary Care Provider: 0.5
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 2.50 contact hours.
Each course is approved for the following number of ANCC credits:
- Medication Treatment for Opioid Use Disorder Credit: 0.75
- Screening for Substance Use Credit: 0.75
- Naloxone in the Pharmacy Setting: 0.5
- Managing Patients’ Pain: Insights from a Primary Care Provider: 0.5
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for a maximum of 2.50 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.
- Medication Treatment for Opioid Use Disorder Universal Activity Number (UAN) #: JA4008162-9999-23-330-H01-P (2023 – 2024)
- 0.75 credit hours
- Screening for Substance Use UAN #: JA4008162-9999-23-331-H01-P (2023 - 2024)
- 0.75 credit hours
- Naloxone in the Pharmacy Setting UAN #: JA4008162-9999-23-332-H01-P (2023 - 2024)
- 0.5 credit hours
- Managing Patients’ Pain: Insights from a Primary Care Provider UAN #: JA4008162-9999-23-333-H01-P (2023 - 2024)
- 0.5 credit hours
Type of Activity: Knowledge
Hardware/Software Requirements:
Content is accessible regardless of internet browser. However, the Google Chrome browser often performs best.Policy on Privacy and Confidentiality:
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.Continuing Dental Education
Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of the credit hours by boards of dentistry. Concerns or complaints about a CE provider may be directed to the provider or to the Commission for Continuing Education Provider Recognition at ADA.org/CERP.
Postgraduate Institute for Medicine designates this activity for a maximum of 2.50 continuing education credits.
Concerns or complaints about a CE provider may be directed to the provider, or to the Commission for Continuing Education Provider Recognition at ADA.org/CERP.
Each course is approved for the following number of continuing education credits:
- Medication Treatment for Opioid Use Disorder Credit: 0.75
- Screening for Substance Use Credit: 0.75
- Naloxone in the Pharmacy Setting: 0.5
- Managing Patients’ Pain: Insights from a Primary Care Provider: 0.5
Computer System Requirements
Content is accessible regardless of internet browser. However, the Google Chrome browser often performs best.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.